UNCY
NASDAQ · Biotechnology
Unicycive Therapeutics Inc
$4.69
-3.01 (-39.09%)
Open$4.00
Previous Close$7.70
Day High$4.92
Day Low$3.93
52W High$8.74
52W Low$3.71
Volume—
Avg Volume1.32M
Market Cap222.68M
P/E Ratio—
EPS$-2.08
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+33.7% upside
Current
$4.69
$4.69
Target
$6.27
$6.27
$3.63
$6.27 avg
$7.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 52.90M | 51.72M | 45.87M |
| Net Income | -11,930,457 | -10,903,389 | -10,566,816 |
| Profit Margin | -22.6% | -21.1% | -23.0% |
| EBITDA | -19,602,786 | -19,995,313 | -16,713,067 |
| Free Cash Flow | -9,449,797 | -9,177,412 | -10,735,832 |
| Rev Growth | -5.2% | +18.0% | +24.4% |
| Debt/Equity | 0.52 | 0.63 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |